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Abstract 
Isaie Sibomana, M.S., Department of Biochemistry and Molecular Biology, Wright State 
University, 2011 
'Functional Metabolomics' Enhances Assessment of Tissue Dysfunction as Demonstrated 
in a Rat Model of Sub-Acute D-serine Exposure 
 
We describe a methodology that combines urinary metabolomics with a tissue-
specific stressor administration to enhance assessment of tissue function. Kidney function 
in rats was mildly compromised with a sub-acute dose of D-serine and stressed with 
furosemide. NMR-based metabolomics analyses showed no detectable effects due to D-
serine alone; but furosemide or D-serine + furosemide groups, classified separately from 
each other, and from control. Furosemide alone caused a ca. 2-fold increase in glucose, 
lactate, choline, and a 30% decrease in TCA intermediates (p≤0.05). D-serine suppressed 
these effects and produced a 1.7-fold increase in a p-phenolic acid-derivative of tyrosine 
(PAdY) relative to control (p≤0.05). The PAdY/tyrosine ratio increased 2-fold relative to 
rats given furosemide alone. D-serine effects were only detectable in furosemide-
challenged rats, suggesting that minor disruption in kidney function, induced by low-
level D-serine, is manifested by this functional metabolomics methodology. This 
technique may improve sensitivity for assessment of tissue function and disease. 
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1. INTRODUCTION 
1.1 Overview on NMR-based metabolomics 
Metabolomics (1, 2), which is also known as metabonomics (3, 4) or metabolic 
profiling (5) is defined as the “quantitative measurement of the time-related multi-
parametric metabolic response of living systems to pathophysiological stimuli or genetic 
modification” (3). NMR-based metabolomics has been used to associate an organism’s 
health status to its metabolite profile measured in biofluids (e.g., urine, blood, fecal and 
tissue extracts) or tissue biopsies. Coupled with multivariate data analyses, the 1H NMR-
based metabolomics approach is a fast, accurate and reproducible analytical technique for 
visualization of biochemical changes in biofluids or tissues (3, 6-12). This methodology 
involves correlating observed changes in metabolite levels to the biological effects 
related to physiological stimuli or genetic modification, toxicological, pathophysiological 
or environmental conditions.  The use of 1H NMR-based metabolomics technique has 
recently gained attention for direct application in preclinical, clinical, environmental and 
biomedical areas (4) due to several advantages that the technique offers such as rapidity 
and simplicity in sample preparation, high reproducibility and direct reflection of 
biological events among others (13). Studies have highlighted its potential for the 
successful identification and characterization of toxicity (14-25), metabolic pathways 
perturbed in various cancers (26-33), disease-related stages in chronic lymphocytic 
2 
 
leukemia (34), and other pathophysiological conditions (10, 35). The power of this 
technique is demonstrated for instance by its ability to detect the biochemical alterations 
induced by drug/chemical exposure and precisely localize the target organ based on the 
changes in metabolite concentrations observed from a peripheral sample such as urine or 
blood (11). In fact, metabolomics constitutes an important tool required to give an insight 
on the impact of various factors that affect the health status such as the genetic 
modifications, exposure to stimuli (e.g., noxious agents, stressors, nutrients, etc), 
toxicological, pathophysiological or environmental conditions (12). 
1.2 Challenges for NMR-based metabolomics approach 
Although the NMR-based metabolomics approach offers clear advantages in 
health assessment and monitoring over the use of traditional clinical assays, it still has not 
been widely implemented in clinical settings. One obstacle to clinical metabolomics 
approaches is the fact that the metabolite profile of various biofluids is influenced by 
numerous factors that may or may not be related to the biological processes of interest. 
These include genetics (36), gender, age, nutrition (12, 37-39), disease processes, 
environment, xenobiotics, (40, 41) and personal factors such as diet, exercise, and use of 
medications, alcohol, tobacco, etc. (7). This high diversity, especially in humans, 
produces a high “background noise” in metabolite profiles, which impedes data 
interpretation.  Thus relating metabolite profiles to health and disease is a formidable 
task.  Some of this variability can be minimized by controlling factors such as diet, or 
imposing strict exclusionary criteria for subjects (i.e., exclude smokers or medications), 
but this has been met with limited success due to numerous uncontrollable factors (42-
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44). Other methods attempt to examine the influence of perturbing factors on metabolite 
profiles (7, 12, 45-47), but data are confounding and incomplete given the complexity of 
the problem. A more promising approach involves longitudinal studies, which have 
provided evidence that individual metabolic phenotypes may exist (48), and their 
detection through multiple sample collection combined with advanced statistical methods 
((49), and reference therein) may provide a means to eliminate the daily ‘metabolomics 
noise’. 
1.3 ‘Functional Metabolomics’ approach 
Although several studies have successfully used NMR-based metabolomics to 
point out differences in metabolite profiles inherent to gender, aging, nutrition (12, 37-
39), toxicity (14-16, 18-25, 43), diseases (10, 32, 34, 35) and other health-related issues, 
there are various factors associated with human health conditions that may affect the 
sensitivity of metabolomics assessment. Thus, to make this technique more useful, there 
is a need to implement a well-designed approach that can enhance its sensitivity, which is 
the basis of this study.  
1.3.1 Hypothesis and Strategy for Functional Metabolomics 
Herein we describe a different approach, dubbed functional metabolomics, 
towards improving the sensitivity of metabolomics for detection of biologically relevant 
effects. This methodology strives to increase the “signal-to-noise” ratio in metabolomics, 
which may potentially improve its usefulness to measure real and meaningful biological 
effects above the daily background variability. We hypothesize that the ability to detect 
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meaningful metabolite alterations, those related to tissue function/dysfunction, can be 
greatly enhanced by applying an organ-specific “metabolic challenge”. The tissue 
response under a metabolically stressed condition will reduce inter-animal variability, 
and augment our capability to detect biologically relevant changes in urinary metabolite 
profiles.  Detection of abnormalities (i.e., tissue dysfunction due to chemical exposure or 
disease) will be enhanced when the stressor is applied. This approach is analogous to a 
glucose tolerance test to check for diabetes. Here, glucose is given as a body’s metabolic 
challenge and the body’s ability to clear the glucose from the blood reflects either normal 
or altered insulin sensitivity.  
We tested this hypothesis in a rat model, using kidney as the target organ and 
furosemide, a diuretic drug, as an exogenous metabolic challenge (tissue stressor). 
Further, we compared normal healthy animals to animals that were exposed to a sub-
acute dose of D-serine, a well-characterized nephrotoxin. This low-dose D-serine 
exposure was undetectable by standard urinary metabolomics analyses. But the mild 
kidney dysfunction in D-serine-treated animals was revealed under the furosemide-
induced (kidney-stressed) condition. Theoretically, this functional metabolomics 
methodology could be extended (1) to evaluate tissues or organ systems other than 
kidney by developing tissue-targeted metabolic stressors, and (2) to detect tissue 
dysfunction due to disease as well as exposure to xenobiotics. 
1.3.2 Why D-serine in this study? 
D-serine is a well-known kidney toxicant that was used in this study at a sub-
acute dose to mildly disrupt kidney function. Several intensive studies have described the 
5 
 
nature of its toxicity in rat models (20-22, 50-52). D-serine is specifically re-absorbed 
into the pars recta (or S3 straight segments) region of proximal tubules where the D-
amino acid oxidase (D-AAO) enzyme is localized (53). Proximal tubular necrosis can 
develop as a result of excessive D-AAO enzymatic metabolism of D-serine, which can 
generate reactive oxygen species and lead to a decrease in the levels of renal glutathione 
(Figure 1) (54).  
A study involving LEA/SENDAI rats that lack D-AAO enzyme highlighted the 
role of this enzyme in D-serine-induced nephrotoxicity as these rats were not affected by 
D-serine exposure when compared to their counterpart F344 rats which were 
characterized by excessive excretion of glucose and urine after being exposed to the same 
dose of D-serine (55). D-serine down-regulates various metabolic pathways such as the 
TCA cycle through inhibition of citrate synthase enzyme (56), resulting in depletion in 
citrate, α-ketoglutarate and succinate (22). D-serine has also been reported to have a 
negative effect on oxidative phosphorylation, ATP synthesis coupled electron transport, 
amino acid transport, metabolism of lipids, nucleotides, vitamins, carbohydrates and on 
oxidative stress response (57). Other studies have also indicated that it induces an  
increase in urinary excretion of glucose, lactate, acetate and alanine (22). The common 
biomarkers of D-serine toxicity observed with rat models include proteinuria, amino 
aciduria, glucosuria (Ganote et al., 1974; Carone & Ganote, 1975). The sub-acute dose of 
D-serine used herein (60 mg/kg) was chosen based upon literature reports and 
preliminary studies in our laboratory. Williams, et al. (21) found no observable 
alterations in urinary metabolite profiles in Alderley Park rats exposed to 62.5 mg/kg D-
serine. Additionally, studies in our laboratory (unpublished data) using Fischer-344 rats 
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showed no effects of D-serine at 50 mg/kg in comparison to 100 mg/kg, which was 
characterized by glucosuria, proteinuria and amino aciduria.  Thus, a dose of 60 mg/kg 
D-serine was expected to be just below the threshold at which measureable effects can be 
observed and was used in this study.  At an effective dose, the maximal D-serine-induced 
nephrotoxicity is observed within 24-48 h post exposure ((21); unpublished data from our 
laboratory).  
 
Figure 1.  Mechanism for D-serine toxicity 
1.3.3 Why Furosemide administration in this study? 
Furosemide is a clinically used diuretic drug and was used here as a mild 
chemical stressor targeting the kidney. Figure 2 shows its chemical structure (58). 
Furosemide reversibly binds to Na+/2Cl-/K+ co-transport proteins in the thick ascending 
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limb of the loop of Henle, reducing the reabsorption of the salt and water, resulting in a 
profound increase in urinary output (59-63). Other studies have suggested an extension of 
furosemide effect to the distal tubules (64, 65). Furosemide is also reported to confer 
renal protection by reducing oxygen requirement through the inhibition of the active 
NaCl transport (66, 67).  By inducing an increase in tubular blood flow, furosemide can 
also drive a decrease in nephrotoxin concentrations (68).  
The time at which furosemide was given to animals was made to coincide with 24 
h post D-serine administration as our laboratory (unpublished data) and other studies (21, 
52) have established that the maximum effect of D-serine toxicity is observable within 
24-48 h of treatment. The dose of furosemide (10 mg/kg) was based upon studies 
showing maximal diuretic effectiveness in rats within 1 hour postdose (69, 70). 
Furosemide was expected to exert a minor pressure on kidney activity, thus helping to 
detect any weakness in kidney function. The use of furosemide in this study is analogous 
to the glucose tolerance test performed in diabetes screenings. As the glucose is given as 
the metabolic challenge and the body’s ability to clear the glucose from the blood reflects 
to which extent the body is normally functioning. Furosemide was expected to expose the 
ability of kidney in handling a D-serine dose characterized as a non-harmful dose.  
8 
 
 
Figure 2. Chemical Structure of furosemide with corresponding proton numbering 
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2. MATERIALS AND METHODS 
The protocols for handling laboratory animals were approved by the Wright-
Patterson Institutional Animal Care and Use Committee (IACUC), and all animal 
experiments were conducted in accordance with federal guidelines. Furosemide was 
purchased from Webster Veterinary, Columbus, OH and D-serine was from Sigma-
Aldrich. Both compounds were prepared in 0.9% sterile saline solution (vehicle). 
Male Sprague-Dawley rats (200 – 225 g) were purchased from Charles Rivers 
Laboratories (Raleigh, NC) and were quarantined (3 days) and allowed to acclimate to 
housing conditions involving a 12 h light-dark cycle at 25 °C with ad libitum access to 
food and water. At 4 days prior to the start of the study, animals were randomly assigned 
to one of four experimental groups (N=12/group) and housed individually in metabolism 
cages. 
2.1 Experimental Design 
The experimental design involved two intraperitoneal (IP) injections (10 ml/kg) 
separated by 24 h, and all animals were also fasted during this 24 h period (Figure 3).  
We chose to fast animals in order to establish a more consistent metabolic state and 
minimize effects due to random feeding among animals; all animals were provided ad 
libitum access to water during the fasting period. Metabolism cages were fitted with 50 
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ml urine collection tubes containing 1 ml of 1% sodium azide, and maintained at 6–10 °C 
using I-Cups (Bioanalytical Systems, Inc., West Lafayette, IN). Three baseline urine 
samples were collected prior to the administration of dosing solutions (at -48, -24 and 0 
h), and daily thereafter. All urine samples were stored at -80 °C until subsequent 
preparation for NMR analysis. On days involving treatments, urine was always collected 
prior to IP injection of animals. For the first injection at t=0, animals were given vehicle 
(Ve) or 60 mg/kg D-serine (Ds), while the second injection at 24 h involved vehicle or 10 
mg/kg furosemide (Fu). The four experimental groups are designated by those treatments 
in which animals received vehicle alone (VeVe), furosemide alone (VeFu), D-serine 
alone (DsVe), or D-serine + furosemide (DsFu). 
 
Figure 3. Schematic diagram of the experimental design depicting times of treatments 
(arrows) and urine collections (U). See text for details. 
11 
 
2.2 Sample Preparation 
Frozen urine samples were thawed at 4 oC overnight. A 600 l aliquot of urine 
was then mixed with 300 l of phosphate buffer (0.2 M mono- and disodium phosphate; 
pH 7.4) and centrifuged at 13,000 rpm for 10 min to remove any precipitates. A 550 l 
aliquot of the supernatant was transferred to a 5 mm NMR tube and mixed with 150 l of 
2,2’,3,3’–tetradeutero-trimethylsilylpropionic acid (TSP) in deuterium oxide (D2O), 
adjusted to yield a final concentration of 2 mM. The TSP served as a chemical shift 
reference ( = 0.00 ppm) and D2O provided a field-frequency lock for NMR data 
acquisition.  
2.3 NMR Data Acquisition and Processing 
All 1H NMR spectra were acquired using a Varian INOVA operating at 600 MHz 
and probe temperature of 25 oC. Water suppression was achieved using the first 
increment of a NOESY pulse sequence, which incorporated saturating irradiation at the 
water resonance frequency during a 2 s relaxation delay (pre-saturation) and again during 
a 50 ms mixing time. A total of 128 transients were collected per spectrum using an 
acquisition time of 4.0 s and inter-pulse delay of 11.05 s. 
Steps involved in 1H NMR data processing and analyses are outlined in Figure 4. 
NMR data were processed using Varian software (VNMR 6.1c) employing exponential 
multiplication (producing line-broadening of 0.30 Hz), Fourier transformation, and phase 
correction. Spectra were then baseline corrected (flattened) in MATLAB (The 
Mathworks, Inc. Natick, MA; v. R2010b) using the Whittaker Smoother algorithm (with 
12 
 
lambda value of 200) on selected spectral noise regions (71, 72). Quantification of 
specific metabolite resonances was accomplished using an interactive spectral 
deconvolution algorithm in MATLAB adapted from our previously described methods 
(73).  The deconvolution tool fits a defined spectral region using a combination of 
tunable baseline shapes (spline, v-shaped, linear, or constant) and a Gauss-Lorentz peak-
fitting function. Integrated areas for peaks of interest are then output to a text file. 
13 
 
 
Figure 4. Steps involved in 1H NMR data processing and analyses 
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Spectral processing for multivariate data analyses included removal of regions 
containing resonances from TSP (at 0.0 ppm), water (4.72 – 5.00 ppm), and urea (5.54 – 
6.01 ppm). We also removed the spectral regions containing resonances from serine (3.82 
– 3.86 and 3.92 – 4.01 ppm; (74) and preliminary studies in our laboratory), since D-
serine was administered to some animals and was expected to be excreted in urine. The 
peak intensities for the remaining metabolite signals of each spectrum were then summed 
to a constant value (sum normalized). To reduce the dimensionality and mitigate peak 
misalignment, a dynamic programming-based adaptive binning technique was employed 
(73) using a minimum and maximum distance between peaks in a single bin of 0.001 and 
0.04 ppm, respectively. Bin boundaries were then manually adjusted to further mitigate 
peak misalignment, and to keep known J-coupled multiplets within that same bin (e.g., 
doublets, triplets, etc). Data were then autoscaled using various datasets as reference 
depending upon which metabolic effects were being investigated (see below). 
2.4 Multivariate Data Analyses 
Multivariate data analyses were conducted on binned, scaled spectral data using 
MATLAB software. Binned NMR data were scaled to a chosen reference dataset by 
subtracting each bin value from the mean value for the corresponding bin in the reference 
data, then dividing this value by the standard deviation of the reference data (auto-
scaling).  The reference data for auto-scaling was chosen to emphasize specific effects 
(details are given in Results). 
Unsupervised Analysis. Principal Component Analysis (PCA) provided a first-
approach, unsupervised technique for data visualization. As previously described (75), 
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our analysis tools enable us to construct a PCA model based on specific experimental 
groups, and then apply the model-specific bin coefficients to other data groups to 
visualize these data relative to the existing model.  To maximize visualization of specific 
responses, we modeled data based upon the nature of the effects being assessed.  For 
instance, to visualize the effects (trajectory in PCA space) related to furosemide 
treatment, a PCA model comprising data from the furosemide-treated group (VeFu) and 
control group (VeVe) at all time points was constructed.  Coefficients generated in this 
PCA model could then be applied to other groups (DsVe and DsFu) to create a trajectory 
into the latent vector space relative to the patterns created by the groups in the model 
(75). PCA scores plots were employed to help identify the time points of maximum 
effects for treatments. 
Supervised Analysis.  Orthogonal Projections onto Latent Structures Discriminant 
Analysis (OPLS-DA) was used to classify data and identify salient features that 
distinguish the various treatment and control groups. In order to apply OPLS-DA, 
spectral data are collected into a matrix of variables or bins (X) and a vector of 
categorical labels (Y), representing the effects.  For these data, the categorical labels were 
treatment and time (e.g., DsFu, 48 h post-dose).  These data were analyzed and modeled 
as follows: (1) determine a specific time point of interest (e.g., 48 h post-dose); (2) 
encode each treatment and corresponding control group as a two-group problem and 
analyze with OPLS (e.g., 1 = DsFu, 48 h post-dose; 2 = VeVe (control), 48 h post-
vehicle); (3) using the model created for this specific two-group problem, project the 
remaining samples from other groups into the OPLS model. 
16 
 
Statistical Evaluation of OPLS Results.  The OPLS model was evaluated on its 
predictive ability, using the Q2 (coefficient of prediction) metric.  Q2 was calculated as 
follows: 

Q2 1
PRESS
SSY
1
yi  ˆ yi 
2
i1
n

yi  y i 
2
i1
n

 
where PRESS is the Predicted REsidual Sum of Squares calculated as the residual e 
between the predicted and actual Y (class labels) during leave-one-out cross-validation, 
SSY is the Sum of Squares for y, 

y  is the y mean across all samples, and ŷi is the y value 
for sample i.  As Q2 approaches 1, the more predictive capability the model exhibits.  A 
Q2 value less than zero indicates that the model has no predictive power. A permutation 
test was performed to evaluate the significance of the Q2 metric.  The test involved 
repeatedly permuting the data labels and re-running the discrimination analysis, resulting 
in a distribution of the Q2 scores (76).  The Q2 from the correctly labeled data is then 
compared to the distribution to determine the significance of the model at a specified 
alpha (set herein at α = 0.01). 
Variable selection (salient bins) from OPLS-DA was also statistically 
evaluated.  The bin loadings, commonly referred to as coefficients, were compared to 
calculated null distributions in order to select for significance.  The null distribution for 
each bin was determined by refitting the OPLS model to datasets in which each bin was 
independently and randomly permuted to remove any correlation between it and the 
control/treatment groups.  The true OPLS model loading was then compared to the 
resulting null distribution of loadings, and values in the tail (greater than 99.5% or less 
17 
 
than 0.5% of the null distribution; corresponding to alpha = 0.01) were assumed to 
contribute significantly to the model.  The permutation was initially repeated 500 times 
for each bin and those near-significant loadings (greater than 92.5% or less than 7.5% of 
the null distribution; corresponding to alpha = 0.15) were selected for 500 additional 
permutations (total 1000). 
2.5 Qualitative assessment of effects related to fasting and re-feeding 
 The control group (VeVe) was used to assess the metabolite changes inherent to 
fasting and re-feeding. Effects of fasting and re-feeding were assessed by comparing the 
urinary spectral intensities obtained from urine samples collected at time 0 h (reference) 
to those collected at 24 h (post fasting) and 48 h (24 h post re-feeding) respectively. Data 
for the reference time point (0 h) and data for fasting or re-feeding were included in the 
supervised OPLS-DA (see details in the section on multivariate analyses) model to 
generate salient features (bins) that classify the two times. Then the NMR spectra from 
the time point of reference and those for fasting or re-feeding were superimposed using 
MATLAB software (The Mathworks, Inc. Natick, MA; v. R2010b). This assessment was 
conducted on sum normalized spectral data. Spectra for these two time points that were 
being investigated were identified by different colors. Then, their spectral intensities in 
each bin were qualitatively compared. The peak intensities for the time point of interest 
(fasting or re-feeding) was scored as decreasing or increasing relative to the referenced 
time (0 h). 
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3. RESULTS 
3.1 Metabolic response to fasting and re-feeding 
Urine samples were collected daily from 48 Sprague-Dawley rats (4 experimental 
groups with N=12/group) for a period of 7 days (see Fig. 3). Serial changes in the mean 
urinary volume outputs for each experimental group are shown in Figure 5. Urine output 
at predose times (-48, -24, and 0 h), and at 72 h and 96 h are similar among all groups.  
Fasting, however, produced a significant increase in urine output (observable at 24 h), 
which returned to baseline levels within 24 h of re-feeding (observable at 48 h). A two-
way repeated measures ANOVA (treatment and time as factors) and Tukey posthoc test 
(p ≤ 0.05) was used to analyze volume changes between predose (represented by the 
average of -48, -24, and 0 h data), 24 h and 48 h time points.  Volume output for all 
groups at 24 h was significantly increased relative to predose (p ≤ 0.05).  This effect, due 
to fasting, has also been reported by others (77). For animals not receiving furosemide 
(VeVe and DsVe), urine output returned to baseline levels by 48 h (within 24 h of re-
feeding). Animals dosed with furosemide (DsFu and VeFu), however, showed 
significantly higher urine output at 48 h (24 h post furosemde treatment) in comparison to 
the control group (VeVe) (p ≤ 0.05).  Thus furosemide was an effective diuretic drug at 
the dose used in this animal model. 
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Figure 5. Changes in 24 h-urinary volume output (Mean ± SD; N=12/group) from Sprague-Dawley rats during the 
experimental protocol diagramed in Figure 3. Data at predose (average of -48, -24, and 0 h time points), 24 h and 48 h were 
analyzed by a two-way repeated measures ANOVA and Tukey HSD posthoc test. Within-group significant differences (p ≤ 
0.05) are denoted by “a” (different from predose) and “b” (different from predose and 48 h).  Groups that are significantly 
different from the control group (VeVe) at 48 h are denoted by “c” (p ≤ 0.05).  
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Unsupervised PCA models depicted in Figures 6 and 7 indicate a common 
clustering of all the groups at 24 h post fasting. However, this clustering of groups was 
separate from the mapping positions at the pre-dose times, depicting the metabolite 
changes that are attributable to fasting conditions. The greatest separation in data was 
observed between pre- and post-fasting times (t=0 and t=24 h, respectively) as well as 
between 24 h and 48 h (24 h post re-feeding). These also were the periods within which 
the highest urinary outputs were collected. As the increase in urine volumes is translated 
into an excretion of diluted metabolites, the metabolic changes associated with fasting 
and furosemide treatment may be broader in scope and modest in magnitude.  
To assess the effects of fasting and re-feeding on the metabolite changes, two 
OPLS-DA models were performed using the control (VeVe) data (Table 1).  The first 
model evaluated the effects of fasting by comparing the data collected at time 0 h (prior 
to fasting) to data for the 24 h time point (post fasting) and the model was significant (Q2 
= 0.93; α = 0.01; accuracy = 96). Impact of re-feeding on the metabolite alterations was 
assessed in a model that compared data obtained at 0 h (baseline) to those collected at 48 
h (post re-feeding) and it was significant (Q2 = 0.95; α = 0.01; accuracy = 100). 
Metabolites in the significant bins that were generated by the two OPLS-DA models are 
listed in Table 1 along with information about their intensity changes. Our study has 
documented a considerable range of metabolites that are decreasing or increasing 
following the fasting or re-feeding periods (Table 1). The red arrow indicates an increase 
in the metabolite intensities while the black arrow depicts a decrease. Fewer metabolites 
(23 metabolites) were out of normal ranges within 24 h post-refeeding period as 
compared to metabolites (32 metabolites) that responded to the 24 h fasting period. Out 
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of 23 metabolites that were altered relative to the baseline, 20 of them were characterized 
by an increase. Similar effects of fasting and re-feeding were characterized by an increase 
of glycolytic products (pyruvate and lactate), amino acids (alanine and 
isoleucine/leucine), acetate, benzoate, allantoin, phenylacetyglycine and creatinine. TCA 
intermediates (citrate and α-ketoglutarate) and hippurate displayed a continuous decrease 
(during fasting and re-feeding). Some of the metabolites that were negatively affected by 
the fasting displayed an increase inherent to re-feeding. These were malonate, creatinine, 
methylguanidine, 3-hydroxyisobutyrate, trigonelline, urocanate, trans-Aconitate and 
homovanillate. Intensity levels of the amino acids such as lysine/arginine and glycine, 
glucose, fumarate, methylamine, dimethylamine, sarcosine, butaine, trimethyl amine 
oxide (TMAO), choline, taurine and pyridoxine were normalized within the 24 h of re-
feeding. Although fasting did not have an effect on the urinary levels of formate, 
trimethylamine and thymidine, re-feeding induced their increase. 
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Table 1. Metabolite changes associated with fasting and re-feeding in control Sprague-
Dawley rats (VeVe group). 
Metabolite Direction of changes relative to baseline (0 h) 
post fasting (at 24 h) post re-feeding (at 48 h) 
Glycolysis   
Glucose ↑ - 
Pyruvate ↑ ↑ 
Lactate ↑ ↑ 
TCA intermediates   
Citrate ↓ ↓ 
α-ketoglutarate ↓ ↓ 
Fumarate ↓ - 
Amino acids   
Alanine ↑ ↑ 
lysine/arginine ↑ - 
isoleucine/leucine ↑ ↑ 
Glycine ↑ - 
Others   
Methylamine ↓ - 
Dimethylamine ↓ - 
Sarcosine ↓ - 
Betaine ↓ - 
TMAO ↓ - 
Hippurate ↓ ↓ 
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Table 1 – Continued   
   
Malonate ↓ ↑ 
Creatine ↓ ↑ 
Methylguanidine ↓ ↑ 
3-hydroxyisobutyrate ↓ ↑ 
Trigonelline ↓ ↑ 
Urocanate ↓ ↑ 
trans-Aconitate ↓ ↑ 
Homovanillate ↓ ↑ 
Choline ↑ - 
Acetate ↑ ↑ 
Taurine ↑ - 
Benzoate ↑ ↑ 
Allantoin ↑ ↑ 
Phenylacetylglycine ↑ ↑ 
Pyridoxine ↑ - 
Creatinine ↑ ↑ 
Formate - ↑ 
Trimethylamine - ↑ 
Thymidine - ↑ 
↑ Increase 
↓ Decrease 
- No change 
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3.2 Metabolic response to D-serine and furosemide treatments 
Figure 6 shows a PCA scores plot (PC1 vs PC2) that models all groups (VeVe, 
DsVe, VeFu, DsFu) at all time points (-48, -24, 0, 24, 48, 72, 96 h). Data were autoscaled 
using all groups at pre-dose times (-48, -24, 0 h) as reference. Trajectories across time are 
mainly due to fasting (at 24 h) and re-feeding (at 48 h) effects, but data return to the 
predose position by 96 h (data at 72 and 96 h are omitted in the plot for clarity).  All 
groups respond equally to fasting as evidenced by a common clustering at 24 h. The 
control (VeVe) and DsVe groups display similar mapping position at all times, indicating 
no observable effect of D-serine treatment in the absence of furosemide. Interestingly, at 
48 h slight differences are observed in mapping positions between groups, which 
presumably reflect changes in urinary metabolite profiles that are induced by furosemide 
and a combination of D-serine/furosemide treatments (VeFu and DsFu groups). 
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Figure 6.  PCA scores plot (PC1 vs. PC2 representing 41% of total variance) based on rat 
urinary NMR spectra from functional metabolomics study. Symbols and ellipses are 
centroid mean ± 2SE; arrows show trajectories across time. Data were autoscaled (see 
Methods) relative to all pre-dose time points (-48, -24, 0 h), and the PCA model includes 
all groups at all time points. Data at 72 h and 96 h are not shown for clarity but follow a 
trajectory towards the pre-dose times. 
Although the D-serine/furosemide and furosemide-induced effects are observable 
at 48 h, they are not fully exposed by this PCA model due to the overwhelming impact of 
fasting/re-feeding animals. In order to suppress the impact of fasting and highlight the 
effects that are attributable to treatments, data were autoscaled relative to VeVe + VeFu 
groups at 24 h (corresponding to the time of maximum effects due to fasting and 
including only animals receiving vehicle solution; note: furosemide was administered 
after the 24 h urine collection).  A PCA model based on these groups (VeVe + VeFu) 
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across all time points (autoscaled relative to 24 h) is shown in Figure 7. Data from DsVe 
and DsFu groups were superimposed in the plot using coefficients derived from the PCA 
model. Clustering of the groups at predose and 24 h times is apparent, similar to the 
results observed in Figure 6 and, as expected, suppressing the effects of fasting resulted 
in better separation between animals receiving furosemide versus vehicle (VeFu and 
DsFu vs. VeVe and DsVe) observed at 48 h. Moreover, the model does not display any 
difference in mapping positions between the control (VeVe) and DsVe groups, again 
indicating the lack of observable effects from D-serine treatment. 
 
 
  
Figure 7. PCA scores plot (PC1 vs. PC2 representing 49% of total variance) based on rat 
urinary NMR spectra for VeVe + VeFu groups at all time points, with data autoscaled 
(see Methods) to these same groups at 24 h. Data from DsVe and DsFu groups were 
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superimposed in the plot using coefficients derived from the PCA model. Symbols and 
ellipses are centroid mean ± 2SE; arrows show trajectories across time. Data at 72 h and 
96 h are not shown for clarity but follow a trajectory towards the pre-dose times. 
Effects due to D-serine and furoseamide treatments should be apparent at 48 h, 
thus we used PCA to model these groups together with the control group (VeVe) at 48 h, 
and autoscaled these data relative to VeVe at 48 h to minimize effects due to re-feeding. 
Groups not included in the model were superimposed in the PCA scores plots (Figure 8) 
using the coefficients derived from the PCA model. Figure 8A and 8B show good 
separation between animals receiving furosemide versus vehicle along PC1 (VeFu and 
DsFu vs. VeVe and DsVe). Again the VeVe and DsVe groups overlap as expected, but 
the groups receiving furosemide alone versus a combination of D-serine + furosemide 
show an emerging separation at 48 h, particularly in Figure 8A.  
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Figure 8. PCA scores plots modeling (A) VeVe + VeFu at 48 h (PC1 vs. PC2 representing 54% of variance), and (B) VeVe + 
DsFu at 48 h (PC1 vs. PC2 representing 39% of variance).  Data for DsVe and DsFu at 48 h are superimposed in plot A, while 
data for DsVe and VeFu are superimposed in plot B using coefficients derived from the PCA models. All data were autoscaled 
(see Methods) relative to VeVe at 48 h, and symbols and ellipses are centroid mean ± 2SE.  
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OPLS discriminant analyses were conducted to evaluate the statistical 
significance and identify the salient features (spectral bins) that are associated with group 
classification at 48 h. The model significance was tested at α = 0.01 and the results, 
displayed in Figure 9 (T vs. T Orthogonal plots), clearly show that animals receiving 
furosemide alone (VeFu) or D-serine + furosemide (DsFu) are significantly different 
from vehicle-treated controls (VeVe) (Fig. 9A and 9B). Indeed, the Q2 values were ≥0.90 
and the predictability accuracy for both models was 100% (leave-one-out cross 
validation). A total of 69 and 43 significant bins (α = 0.01) were derived from VeVe vs. 
VeFu and VeVe vs. DsFu OPLS-DA models, respectively.  An OPLS-DA for VeFu vs. 
DsFu at 48 h also yielded a significant result (Q2 = 0.44; Accuracy = 100%) and 
generated 23 salient bins responsible for group classification (Fig. 9C).  In a further 
analysis, we tested for correlation between the coefficients for these 23 significant bins 
found by OPLS-DA (Fig. 9C) and the loadings for principal component 1 from the PCA 
displayed in Fig. 5A, which showed a slight separation between VeFu and DsFu groups. 
Interestingly, Spearman’s Rank Correlation showed these coefficients to be highly 
correlated (Spearman || = 0.7194; p = 0.0001) indicating that the unsupervised PCA and 
supervised OPLS-DA models are finding similar features to classify the effects of 
furosemide alone (VeFu) and a combination of D-serine + furosemide (DsFu). In each of 
the OPLS model plots shown in Figure 9, we superimposed data from the other groups 
not included in the model.  As expected, VeVe and DsVe were clustered together similar 
to the PCA results.  Additionally, an OPLS-DA for VeVe vs. DsVe was not significant 
(Q2 = 0.012; p = 0.01), confirming that no significant effects from D-serine treatment 
alone were observable. 
30 
 
All the significant bins derived from the three OPLS-DA models (Fig. 9A, 9B and 
9C) are shown in a Venn diagram (Fig. 9D) to illustrate the number of common and 
unique features derived from these models.  Figure 10 depicts all the combinations of 
OPLS-DA models used in the extraction of the salient features that classify the VeVe, 
VeFu and DsFu groups. The analyses that classify and separate VeFu from VeVe (Fig. 
9A) and DsFu from VeVe (Fig. 9B) yield 86 distinct bins, 26 of these are shared 
(identical bins) between the two models (Fig. 10).  Presumably, these 86 bins are 
important for the classification of VeFu, DsFu and VeVe. Therefore, we conducted 
analyses similar to those presented in Figure 8, but used only these 86 significant bins as 
input to PCA.  These PCA scores plots (data not shown) appear similar to those in Figure 
8, which used all 267 spectral bins in the PCA models. Focusing on the clustering 
observed for VeFu and DsFu at 48 h, with an aim towards determining which bins are 
responsible for group classification, we again conducted OPLS-DA. An OPLS-DA model 
for VeFu vs. DsFu at 48 h using this limited set of 86 bins (OPLS scores plot not shown) 
is statistically significant (Q2 = 0.51; accuracy = 96%) and yields 23 significant bins 
[shown in Fig. 10 as (B)] when the model significance is tested at α = 0.01.   Ten of these 
23 bins are common (identical) to a set of bins that are derived from the same model, but 
using all 267 spectral bins [shown in Fig. 10 as (A)]. In other words, each of the two 
models (OPLS using 267 bins and OPLS using 86 bins as input) generates 13 unique 
features in addition to 10 shared features, yielding a total of 36 bins that drive the 
separation of VeFu and DsFu at 48 h (Fig. 10). 
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Figure 9. OPLS-DA models using rat urinary NMR spectra at 48 h with all data autoscaled to the control group (VeVe) at 48 
h. (A) VeVe vs. VeFu (Q2 = 0.95); (B) VeVe vs. DsFu (Q2 = 0.90); and (C) DsFu vs. VeFu, (Q2 = 0.44).  Models A, B, and C 
are all statistically significant (test α = 0.01; see Methods) and yield an accuracy of 100% (leave-one-out validation). Large 
symbols depict data from the modeled groups, while other groups superimposed in the model are shown in smaller symbols.  
The number of significant bins determined by the OPLS-DA model (α = 0.01; see Methods) is indicated in each plot, and also 
displayed in a Venn Diagram (D).  
D 
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Figure 10. Diagram that depicts all the combinations of OPLS-DA models used in the 
extraction of the salient features that classify the control (VeVe), furosemide (VeFu) and 
D-serine + furosemide (DsFu) groups at 48 h. 
Taken together, we find a total of 26 bins that are important for classifying VeFu 
and DsFu groups separately from vehicle control (VeVe) and an additional 36 features 
that are important for separating VeFu and DsFu groups at 48 h (see Fig. 10). Figure 11 
shows PCA scores plots (PC1 vs PC2) based on a combination of all these features (26 + 
36 = 62 bins; Fig. 11 A) and a total of 267 bins (Fig. 11 B). The PCA models include 
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VeVe + VeFu + DsFu at 48 h.  The model constructed using 62 bins (Fig. 11 A) shows a 
clear distinction between VeVe, VeFu and DsFu groups. But when the DsVe group is 
superimposed in this model, these data overlap with the control group (VeVe).  Thus 
there is a lack of observable effects from D-serine treatment alone, but in combination 
with furosemide distinct metabolic changes are observable that appear to be associated 
with 36 features.  These 36 features may represent the salient urinary metabolite changes 
that reflect mild kidney dysfunction induced by exposure to low-dose D-serine. A 
comparison between the PCA scores plot shown in Figure 11 A to the PCA scores plot 
generated using all the 267 spectral bins (Fig. 11 B) indicates that a clear classification of 
the groups is obtained when the PCA model is based on a selection of 62 bins.  
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Figure 11. PCA scores plots modeling VeVe + VeFu + DsFu groups at 48 h with data autoscaled (see Methods) relative to 
VeVe at 48 h. (A) the PCA model uses a total of 62 bins selected by OPLS-DA (see text for details; PC1 vs. PC2 representing 
59 % of total variance). (B) the PCA model uses all 267 spectral bins (PC1 vs. PC2 representing 43 % of total variance). Data 
from the DsVe group are superimposed in both plots using coefficients derived from the PCA models. 
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NMR spectral regions identified as significant by OPLS-DA were compared 
between experimental groups, and specific resonances were assigned to metabolites with 
the aid of literature, on-line databases (HMDB, http://www.hmdb.ca/), and Chenomx 
NMR Suite software (Edmonton, Alberta, CA).  We analyzed the 36 significant bins 
derived from the OPLS-DA that emphasize the effects of D-serine observable in the 
presence of furosemide (VeFu vs. DsFu at 48 h).  From these 36 bins we assigned 11 
unique independent metabolites (some bins contained redundant information since 
multiple peaks were detected from the same metabolite) plus one additional signal that 
could not be identified. These 12 metabolite signals were quantified (integrated peak 
areas) using a spectral deconvolution/peak-fitting algorithm (see Methods). It is important 
to note that, because of the sum normalization procedure (see Methods), metabolite 
intensities are represented as a fraction of the total urinary metabolite pool in each 
sample. Table 2 displays these metabolite data expressed as a ratio of the treatment group 
(VeFu or DsFu) relative to control (VeVe) at 48 h. Table 2 also differentiates those data 
determined to be statistically significant by OPLS-DA for specific treatment vs. control 
groups, and those found to be significant when analyzed by peak integration and t-test 
(superscripts a and b, respectively). Relative to the control group (VeVe), furosemide 
treatment alone (VeFu) caused a ca. 2-fold increase in lactate, glucose, and choline, and a 
30% decrease in citrate. These effects appear to be mitigated in the group exposed to D-
serine prior to furosemide (DsFu) and, instead, this group shows a 1.7-fold increase 
(relative to VeVe) in a doublet signal at 6.83 ppm, which is characteristic of aromatic 
protons on a para-substituted phenol. This metabolite is likely to be a p-phenolic acid 
derivative of tyrosine such as 4-hydroxyphenylpropionic acid (desaminotyrosine), 4-
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hydroxyphenylpyruvic acid (HPPA), or 4-hydroxyphenyllactic acid (HPLA). 
Desaminotyrosine seems an unlikely candidate since its source is microbial (gut 
microbial metabolism of tyrosine). Figure 12 shows the tyrosine metabolism pathway that 
generates the HPPA and HPLA compounds.  These compounds are produced in kidney 
by transamination of tyrosine via tyrosine aminotransferase to yield HPPA, which can be 
reduced to HPLA by 4-hyrdroxyphenyllactate dehydrogenase.  Others have also observed 
these metabolites in NMR spectra of rat urine under experimental conditions involving 
perturbations to the tyrosine catabolism pathway (20, 78). We could not unequivocally 
assign this metabolite since resonances from its aliphatic protons were obscured in 
densely populated regions of the spectrum. Therefore, we will refer to this metabolite as a 
p-phenolic acid derivative of tyrosine (PAdY).   
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Table 2. Changes in 12 urinary metabolites (U, unidentified) identified from 36 
significant bins (some metabolites yielded signals in multiple bins) derived from OPLS-
DA for comparisons between experimental groups at 48 h (see text for details). Values 
are reported as a fold-change ratio for treated (VeFu or DsFu) versus control (VeVe) 
groups. Peak multiplicities are indicated as:  s, singlet; d, doublet; dd, double of doublet; 
t, triplet. Standard rules for propagation of errors were used to determine the ±SE for 
calculated ratios. 
Metabolite 
Chemical 
Shift in ppm 
Fold Change (Mean ± SE) 
VeFu/VeVe 
ratio 
DsFu/VeVe 
Ratio 
Lactate 1.33 (d) 2.2 ± 0.6 a, b 1.2 ± 0.2 a 
Glucose 4.66 (d) 1.7 ± 0.3 a, b 1.3 ± 0.2 a 
Choline 3.20 (s) 1.6 ± 0.2 a, b 1.3 ± 0.1 a, b 
Tyrosine 3.16 (d) 1.2 ± 0.1 a 1.1 ± 0.1 a 
PAdY 1 6.83 (d) 0.9 ± 0.2 a 1.7 ± 0.3 b 
Phenylacetylglycine 7.36 (t) 0.9 ± 0.1 a 1.2 ± 0.2 a 
Homovanillate 6.76 (dd) 0.9 ± 0.1 a 1.1 ± 0.1 a 
Unknown 7.46 (s) 0.9 ± 0.1 a 0.9 ± 0.1 
Citrate 2.55 (d) 0.7 ± 0.1 a, b 1.0 ± 0.1 
Dimethylglycine 2.93 (s) 0.7 ± 0.2 a 0.8 ± 0.2 
Tryptophan 7.22 (t) 0.7 ± 0.1 a 0.8 ± 0.1 a 
histidine + N,N-methylhistidine1 7.07 – 7.05 0.7 ± 0.1 a 0.9 ± 0.1 
1 A p-phenolic acid derivative of tyrosine (see text for details). 
a Significant bins from OPLS-DA for each specific treatment group vs. control (Q2 ≥ 
0.90; p ≤ 0.01). 
b Significant difference in treated vs. control for quantified metabolite signal (t-test, p ≤ 
0.05). 
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We also measured metabolite ratios within each urine sample for the VeVe, VeFu, 
and DsFu groups at 48 h (Table 3). We focused on those metabolites deemed important 
via OPLS-DA procedures and based ratios relative to the urinary creatinine level, or 
between metabolites that share a common pathway (e.g., homovanillate/tyrosine; 
PAdY/tyrosine; glycine + dimethylglycine/choline). In general, amino acids (represented 
as: tyrosine + tryptophan + histidine + N,N-methylhistidine) are decreased in the VeFu 
and DsFu groups relative to the vehicle control group (VeVe). Furosemide alone (VeFu) 
also caused a decrease in the citrate/creatinine ratio relative to the VeVe group. 
Therefore, we chose to measure other TCA (tricarboxylic acid cycle) metabolites that 
-ketoglutarate (2.45 ppm), succinate (2.41 
ppm), and fumarate (6.53 ppm). The sum of these TCA inte -
ketoglutarate + succinate + fumarate) expressed as a ratio to creatinine was also 
significantly decreased in the VeFu group relative to control. These metabolite ratios, 
however, were unaffected in the DsFu group. The sum of glycine and dimethylglycine 
expressed as a ratio to choline (glycine + dimethylglycine/choline) was also reduced in 
the VeFu group relative to control (VeVe), but this ratio was again unaffected in the 
DsFu group. Interestingly, the PAdY/tyrosine ratio in the DsFu group was not different 
from the control (VeVe) value, but was 2-fold higher in comparison to the VeFu.    
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Table 3. Urinary metabolite ratios (Mean ± SE) for VeVe, VeFu, and DsFu experimental 
groups measured at 48 h. 
Metabolite Ratios VeVe VeFu DsFu 
lactate / creatinine 0.5 ± 0.1 0.8 ± 0.2 0.4 ± 0.1 
glucose / creatinine 0.3 ±  0.1 0.3 ±  0.1 0.3 ± 0.1 
phenylacetylglycine / creatinine 0.2 ±  0.1 0.2 ±  0.1 0.2 ±  0.1 
citrate / creatinine 3.2 ± 0.2 1.7 ± 0.2 a 2.4 ± 0.3 
TCA intermediates / creatinine 1 21.2 ± 3.0 9.9 ± 1.3 a 19.3 ± 3.1 b 
Relevant amino acids / creatinine 2 0.5 ± 0.1 0.3 ±  0.1a 0.3 ±  0.1 a 
glycine + dimethylglycine / choline 8.3 ± 1.0 5.5 ± 0.7 a 6.9 ± 1.0 
homovanillate / tyrosine 1.1 ± 0.1 0.8 ± 0.1 1.0 ± 0.1 
PAdY / tyrosine 0.3 ±  0.1 0.2 ±  0.1 0.4 ±  0.1 b 
1 TCA intermediates = citrate + α-ketoglutarate + succinate + fumarate. 
2 Relevant amino acids = tyrosine + tryptophan + histidine + N,N-methylhistidine. 
a Significantly different from the control (VeVe) group (t-test and Bonferroni correction; 
p ≤ 0.05). 
b Significantly different from the VeFu group (t-test and Bonferroni correction; p ≤ 0.05). 
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4. DISCUSSION 
This study combined a tissue-targeted metabolic challenge (stressor) and NMR-
based metabolomics to investigate whether this approach could enhance sensitivity to 
detect tissue dysfunction. We used an animal model and targeted kidney with a diuretic 
stressor (furosemide) and induced mild tissue dysfunction with a known kidney toxicant 
(D-serine). The experimental protocol also included a 24-h fasting period in an attempt to 
reduce baseline variability in urinary metabolite profiles. Since the main focus of this 
study was not to assess the effects of fasting/re-feeding, we did not elaborate on these 
effects. Thus, we are reporting here simply the results on the qualitative assessment of 
effects related to fasting and re-feeding. 
4. 1 Fasting and furosemide treatment mediate an increase in urinary volume 
output  
Fasting and re-feeding animals induced significant metabolic effects, which 
nearly masked our capability to detect changes due to treatments. As seen in Figure 5, 
fasting also caused a significant increase in urinary volume output, which is consistent 
with previous reports in Sprague-Dawley rats (77, 79). A 2.4-fold increase in urine 
volumes was observable in the samples collected from fasted rats relative to the baseline 
samples. A 2-fold increase in urine volume for overnight (16 h) fasted Sprague-Dawley 
rats has also been documented (77). The mechanism for this fasting-induced urine 
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increase is well established and associated with a decrease in renal aquaporin proteins, 
and imbalance in the regulation of water reabsorption (79, 80).  
As expected, furosemide treatment also caused a transient increase in urinary 
output at 24 h postdose (t=48 h in Fig. 5), with levels returning to baseline by the next 
urine collection time (t=72 in Fig. 5). The diuretic nature, metabolism and molecular 
basis of furosemide have been well characterized (61, 63-65, 70, 81, 82).  The target and 
mechanism of these effects involves reversible binding of furosemide to luminal 
Na+/2Cl–/K+ symporters in the thick ascending limb of the loop of Henle (59-63). 
Another portion of the nephron, the proximal tubules, is the target of D-serine 
nephrotoxicity. 
4. 2 Fasting and re-feeding induce an alteration in urinary metabolite levels 
Fasting has been found to be associated with down-regulation of the renal water 
channel (aquaporins), thus resulting in a decrease in water reabsorption (79). This 
decrease in water re-uptake can explain an increase in urine volumes we observed with 
the fasted rats. The current study performed a qualitative assessment of the effects related 
to fasting and re-feeding. The study documented a considerable range of metabolite 
changes due to fasting and re-feeding. Fasting induced an increase in urinary excretion of 
glucose, pyruvate, lactate and amino acids such as alanine, lysine/arginine, 
isoleucine/leucine and glycine. An increase in urinary excretion of other metabolites such 
as choline, acetate, taurine, benzoate, allantoin, phenylacetylglycine, pyridoxine and 
creatinine was also observed following the 24 h fasting period. Several studies have 
reported a wide range of metabolic changes that are associated with fasting (77, 83-89). 
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Boedigheimer and colleagues (89) have identified fasting as one of the most significant 
sources of variation in gene expression levels. Most recently, Robertson and coworkers 
(77) showed that fasting of rats produced changes in most of the urine metabolites 
detected in NMR spectral profiles, although the magnitude of these changes was 
relatively small. Other studies have reported a fasting-induced down-regulation of several 
proteins involved in glycolysis in male Wistar rats (90) and mice (88). Lenaerts et al. 
(2006) have documented changes in protein expression levels and amino acid metabolism 
that were inherent to 24 h fasting effects. They observed a down-regulation of initiation 
translation factors, thus suggesting an inhibition of protein synthesis (91). This could 
probably explain the increase of amino acid excretion we observed in our study. We also 
noted that fasting induced a decrease in certain TCA intermediates such as citrate, α-
ketoglutarate and fumarate and a set of 14 other metabolites as listed in Table 1. A 
decrease in TCA intermediates following fasting has also been documented by other 
studies (77, 90). Robertson and coworkers (77) have identified alteration in several genes 
that encode the TCA cycle enzymes including a decrease of citrate synthase. Currently, 
the fasting-induced decrease in TCA cycle intermediates is not well understood. Many of 
these TCA intermediates and other metabolites such as acetate, creatinine, hippurate, 
lactate, taurine, trimethyl amine oxide (TMAO) are among the metabolite that have been 
characterized as “usual suspects”   as they frequently change in response to any treatment 
(22). Fewer metabolites (23 metabolites) were out of normal ranges within 24 h post-
refeeding. Most of them (20 metabolites) were characterized by an increase in intensity. 
Only three metabolites (citrate, α-ketoglutarate and hippurate) displayed a continuous 
decrease. The differences in normalization of metabolites after a period of fasting may 
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reflect the differential enzymatic adaptations to re-feeding. Studies have demonstrated 
that the rates of glucose metabolism are enhanced during re-feeding (92-95). However, 
the energy restoration may depend upon carbohydrate absorption since it has been 
demonstrated that an inhibition of carbohydrate absorption in male Sprague-Dawley rats 
correlates with a delay in the energy accumulation following re-feeding (96).  
4. 3 Low-dose D-serine effects are only observable in metabolically stressed kidney 
In this study, D-serine was used to mildly compromise kidney function. Studies 
have shown that the maximum effect of D-serine toxicity as manifested in rat urinary 
metabolite profiles is observable within 24 – 48 h post-exposure at doses ≥100 mg/kg, 
with non-observable effects for doses ≤ 62.5 mg/kg ((21), and unpublished data from our 
laboratory). Based upon these previous studies, the selected sub-acute D-serine dose (60 
mg/kg) in the current study was not expected to cause any observable effects in normal 
healthy rats.  This outcome was confirmed. D-serine treatment alone (DsVe group) 
showed no significant changes in urinary metabolite profiles in comparison to 
corresponding controls (VeVe group) when examined by PCA or OPLS-DA (Figs. 6-10). 
The goal of this study was to test whether this functional metabolomics approach 
can enhance the sensitivity of NMR-based metabolomics to detect slight changes in 
kidney function that may only be detectable under a metabolically stressed condition. 
Thus we focused on extracting the urinary metabolite changes that are unique in 
classifying the VeFu and DsFu groups. Interestingly, PCA and OPLS-DA models 
generated distinct mapping positions for the VeVe, VeFu, and DsFu groups at the 48 h 
time point. This time corresponds to 48 h post D-serine and 24 h post furosemide 
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treatment. These differences in mapping positions support our hypothesis that D-serine-
induced temporal metabolite changes are observable only when the kidney is 
metabolically stressed. Most importantly, we find that the significant features (bins) 
leading to separation between the VeFu and DsFu groups, as derived from a supervised 
OPLS-DA, are highly correlated with the loadings from an unsupervised PCA 
(Spearman’s Rank; p = 0.0001). Thus supervised and unsupervised analyses found 
similar variables that are important for group classification. Through a step-wise 
progression of multivariate data analyses, we identified 36 significant bins derived from 
the OPLS-DA models that appear to be associated with D-serine-mediated disruption of 
kidney function. A detailed spectral analysis assigned these changes to 12 metabolites 
that are influenced by treatments (furosemide alone or D-serine + furosemide). In normal 
functioning kidney, furosemide caused a significant increase in glucose, lactate, and 
choline, and a decrease in citrate (Table 2; VeFu/VeVe ratio). But in rats exposed to D-
serine in combination with the metabolic stress associated with furosemide (DsFu group), 
all of these metabolite changes were abolished, with the exception of choline (Table 2; 
DsFu/VeVe ratio). These results suggest that D-serine disrupted, or mitigated, the normal 
response to furosemide. The glycine+dimethylglycine/choline ratio was also significantly 
reduced by furosemide treatment (Table 3), an effect not observed in the DsFu group 
(these metabolites share a common pathway). 
With regard to effects on glucose, others have also reported a furosemide-induced 
increase in glucose excretion in rats (97-100), mice (101), human (98, 102), and cell-free 
preparations obtained from rabbit kidney (98). Jacobs, et al. (100) have suggested that 
this effect of furosemide may involve inhibition of glucose transport through a direct 
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inactivation of its carrier proteins. Whatever the cause of this effect on glucose excretion, 
it is mitigated by low-dose D-serine exposure (i.e., not observed in the DsFu group). 
Urinary metabolite ratios were also calculated for glucose, lactate, citrate, TCA 
intermediates, and several amino acids (termed relevant amino acids) that were found to 
be important (by OPLS-DA) for detection of any functional abnormalities of kidney 
induced by D-serine. These metabolite ratios were measured relative to creatinine, as 
urinary creatinine clearance has been regarded as an indicator of renal injury (103, 104), 
and creatinine was not among the significant features found by our OPLS-DA models. 
Citrate and TCA intermediates, whether measured relative to the total urinary metabolite 
pool (Table 2) or expressed relative to creatinine (Table 3), were decreased by 
furosemide treatment alone but were unaffected in the DsFu group. Thus this furosemide-
associated metabolic effect appears to be mitigated by D-serine (observable only when 
the kidney is metabolically stressed by furosemide). Although lactate and glucose were 
increased by furosemide when expressed as a fraction of the total urinary metabolite pool, 
the lactate/creatinine and glucose/creatinine ratios were not different from controls. This 
prompted us to measure the stability of creatinine within these experimental groups. 
Indeed, treatment caused a significant increase in creatinine relative to controls 
(VeFu/VeVe = 1.3 ± 0.1 and DsFu/VeVe = 1.5 ± 0.2; Mean ± SE, p ≤ 0.001), but these 
changes in creatinine were not found to be a significant feature for OPLS-DA group 
classification. Reports regarding creatinine clearance in patients receiving furosemide 
treatment vary (66, 68, 105), and creatinine has been listed among the “usual suspects” 
that can frequently change in response to xenobiotics (4). Nonetheless, it is instructive to 
consider these data, particularly the TCA intermediate/creatinine ratio, which is 
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significantly reduced in the VeFu group relative to VeVe or DsFu. These results 
emphasizes the importance of the effects observed for citrate and TCA intermediates, as 
these metabolites are not affected in the DsFu group even though creatinine levels 
significantly rise in this same group. Thus D-serine exposure impacts urinary excretion of 
TCA intermediates — an effect that is only observable when the kidney is metabolically 
challenged with furosemide. These results are interesting in light of the effects of D-
serine nephrotoxicity observed at higher doses (≥100 mg/kg) (21), which include 
increased urinary excretion of glucose and lactate, and decreases in TCA intermediates 
(similar to that seen here with furosemide treatment alone). Thus the metabolite 
perturbations expected with high-dose D-serine alone (toxic dose) or furosemide alone, 
are suppressed in rats receiving low-dose D-serine followed by furosemide challenge.  In 
contrast, the perturbation on creatinine excretion induced by furosemide (e.g., increased 
urinary excretion), was not affected by prior administration of low-dose D-serine. Thus 
some metabolic processes were perturbed while others were not, which may be related to 
differences in the specific sites of action for D-serine and furosemide in the nephron.  
Regardless, these metabolite perturbations reflect abnormalities in kidney function 
imposed by low-dose D-serine, which are only observable when the kidney is stressed by 
furosemide. 
A significant and unique metabolic effect observed in the DsFu group relates to 
the excretion of a p-phenolic acid derivative of tyrosine (PAdY), presumably HPPA 
and/or HPLA (Fig. 12). These metabolites of tyrosine degradation have been observed 
previously in NMR spectra of rat urine following inhibition of 4-hydroxyphenylpyruvate 
dioxygenase (20, 78), the second enzyme in the tyrosine catabolism pathway that 
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converts HPPA to homogentisate. Although the PAdY metabolite might also be 
desaminotyrosine, we believe this is unlikely since it is produced via deamination of 
tyrosine occurring only in gut microbes. Regardless of its origin, a significant increase in 
urinary excretion of the PAdY metabolite was only observed in rats exposed to D-serine 
and then challenged with furosemide to stress the kidney. The DsFu group showed a 1.7-
fold increase in PAdY relative to controls (Table 2), and the PAdY/tyrosine ratio was 2-
fold higher in the DsFu group relative to the VeFu group (Table 3). Urinary excretion of 
tyrosine and PAdY in rats receiving D-serine alone was not different in comparison to 
vehicle controls (DsVe/VeVe ratio = 1.3 ± 0.2 and 1.1 ± 0.2 for tyrosine and PAdY, 
respectively, and the PAdY/tyrosine ratio = 0.2 ± 0.03 and 0.3 ± 0.04 for the DsVe and 
VeVe groups, respectively; no significant difference between groups, p ≤ 0.05, t-test). 
Thus, furosemide alone or D-serine alone did not affect tyrosine or PAdY urinary 
excretion. These results provide evidence that the plasma levels of tyrosine and PAdY are 
unaffected by these treatments (albeit we did not measure plasma metabolites), 
suggesting that the differences seen in the DsFu group reflect altered kidney function 
with regard to tyrosine metabolism, or the excretion of tyrosine and its derivatives. We 
speculate that low-dose D-serine induces a minor insult to renal tubules that, when 
combined with the additional stress imposed by furosemide, perturbs the clearance of 
phenolic acids.  Interestingly, Williams, et al. (20) reported a perturbation in the normal 
handling of phenolic acids following severe renal damage induced by 250 mg/kg D-
serine in rats, which was only observed in the presence of an enzyme inhibitor of tyrosine 
metabolism in kidney. In their study, inhibition of 4-hydroxyphenylpyruvate dioxygenase 
caused increased production and urinary clearance of phenolic acids (HPPA and HPLA) 
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in normal functioning kidney. But following D-serine-induced kidney damage, rats 
instead displayed tyrosinuria with minimal excretion of phenolic acids. Thus it is possible 
that some perturbation in the normal handling and excretion of phenolic acids also occurs 
at a sub-acute dose of D-serine, but this effect is only manifested under an additional 
metabolic stress to the kidney (e.g., furosemide). This may represent a unique effect 
associated with tubular damage, which would not have been observed without the 
functional metabolomics methodology described herein. Further studies would be of 
interest to investigate whether the use of phenolic acids as a kidney stressor would be a 
more useful and sensitive means to assess kidney function/dysfunction. 
One might argue that the effects observed here are unique because they reflect the 
combined treatment of D-serine plus furosemide; however, we believe this is unlikely 
since the tissue accumulation, injury, and clearance of D-serine is rapid and occurs prior 
to administration of furosemide 24 h later. William, et al. (21) reported that maximal 
levels of serine were present in the rat kidney within 30 min of dosing and the first signs 
of tissue injury appear at about 1 h. Additionally, 17% of the administered dose was 
excreted within the first 8 h, and rats showed recovery from D-serine toxicity beginning 
at 24 h. Others have also reported rapid urinary clearance of D-serine in rats, with 28% 
excreted within 24 h (106). Thus, we believe that the effects observed in our study reflect 
abnormalities in kidney function induced by low-dose D-serine, prior to administration of 
furosemide. Another matter to consider is possible bias of our experimental design, which 
used an optimal timing for D-serine and furosemide dosing. In other words, the maximal 
effect of D-serine was expected to occur at 24 h postdose, which was chosen to coincide 
with the furosemide challenge. This likely influenced the results since D-serine-related 
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effects at this dose are temporal. But this may not be a critical factor that compromises 
the utility of the methodology if it is used to screen for persistent tissue abnormalities. 
Further studies are necessary to investigate the relationship between tissue function and 
the timing of the metabolic challenge. 
 
Figure 12. The tyrosine catabolism pathway  
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5. CONCLUSIONS 
By combining a kidney-targeted metabolic challenge (tissue stressor) with urinary 
metabolomics analyses, we demonstrated enhanced sensitivity for detection of functional 
abnormalities in kidney that may be attributed to low-dose D-serine exposure. In 
summary, D-serine mitigated effects of furosemide on urinary excretion of glucose, 
lactate, and TCA intermediates. And D-serine caused a unique effect on tyrosine 
metabolism that was not observable in the absence of the stress imposed by furosemide. 
Although this functional metabolomics approach was limited to kidney, and used a very 
specific means to compromise kidney function (exposure to a nephrotoxin), our results 
are encouraging and can potentially be extended to other organ systems and functional 
abnormalities (i.e., disease pathophysiologies). 
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